Literature DB >> 28279468

Radiation Therapy for Locally Advanced Esophageal Cancer.

Stephen G Chun1, Heath D Skinner2, Bruce D Minsky2.   

Abstract

The treatment of locally advanced esophageal cancer is controversial. For patients who are candidates for surgical resection, multiple prospective clinical trials have demonstrated the advantages of neoadjuvant chemoradiation. For patients who are medically inoperable, definitive chemoradiation is an alternative approach with survival rates comparable to trimodality therapy. Although trials of dose escalation are ongoing, the standard radiation dose remains 50.4 Gy. Modern radiotherapy techniques such as image-guided radiation therapy with motion management and intensity-modulated radiation therapy are strongly encouraged with a planning objective to maximize conformity to the intended target volume while reducing dose delivered to uninvolved normal tissues.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Dose-escalation; Esophageal cancer; IMRT; Radiation

Mesh:

Year:  2017        PMID: 28279468     DOI: 10.1016/j.soc.2016.10.006

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  9 in total

1.  Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases.

Authors:  Guillaume Peyraga; Delphine Caron; Thibaut Lizee; Yann Metayer; Anne-Lise Septans; Yoann Pointreau; Fabrice Denis; Gerard Ganem; Cedrik Lafond; Sophie Roche; Olivier Dupuis
Journal:  Support Care Cancer       Date:  2017-12-23       Impact factor: 3.603

2.  CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR.

Authors:  Wen-Jun Qin; Yi-Ge Su; Xiao-Long Ding; Ren Zhao; Zhi-Jun Zhao; Yan-Yang Wang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

3.  Efficacy and Safety of Simultaneous Integrated Boost Intensity-Modulation Radiation Therapy Combined with Systematic and Standardized Management for Esophageal Cancer.

Authors:  Wenzhao Deng; Xueyuan Zhang; Jingwei Su; Chunyang Song; Jinrui Xu; Xiaohan Zhao; Wenbin Shen
Journal:  Front Surg       Date:  2022-05-23

4.  NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc.

Authors:  Yuwen Wang; Jingjing Cheng; Dan Xie; Xiaofeng Ding; Hailing Hou; Xi Chen; Puchun Er; Furong Zhang; Lujun Zhao; Zhiyong Yuan; Qingsong Pang; Ping Wang; Dong Qian
Journal:  Cancer Commun (Lond)       Date:  2018-06-05

5.  Optimization of Minimum Segment Width Parameter in the Intensity-Modulated Radiotherapy Plan for Esophageal Cancer.

Authors:  Jun Hong; Ji-Hua Han; Hong-Lei Luo; Ya-Qi Song
Journal:  Int J Gen Med       Date:  2021-12-16

6.  Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.

Authors:  Zhenhuan Zhao; Yixue Wen; Dongbiao Liao; Jidong Miao; Yan Gui; Hongwei Cai; Yang Chen; Min Wei; Qiang Jia; Honggang Tian; Mingqiang Sun; Yu Zhang; Gang Feng; Xiaobo Du
Journal:  Oncologist       Date:  2020-09-28

7.  Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.

Authors:  Chih-Yi Chen; Chia-Chin Li; Chun-Ru Chien
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754

8.  Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study.

Authors:  Xiangpan Li; Huibo Zhang; Xuemei Jia; Liming Xu; Huali Liu; Liang Chen; Qibin Song; Zhouguang Hui
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

9.  Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.

Authors:  Chen Li; Lijun Tan; Xiao Liu; Xin Wang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Nan Bi; Lei Deng; Wenqing Wang; Tao Zhang; Wenjie Ni; Xiao Chang; Weiming Han; Zefen Xiao
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.